Raltitrexed-based chemotherapy for advanced colorectal cancer

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 2, 2014, Pages 219-225

  Liu, Y ^a   Wu, W ^a   Hong, W ^a   Sun, X ^a   Wu, J ^a   Huang, Q ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Chemotherapy; Meta analysis; Raltitrexed

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COCHRANE LIBRARY; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LIVER DISEASE; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SKIN MANIFESTATION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; NAUSEA; PATHOLOGY; TOXIC HEPATITIS; VOMITING;

ALOPECIA; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; FLUOROURACIL; HUMANS; LEUCOVORIN; MUCOSITIS; NAUSEA; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMATITIS; THIOPHENES; VOMITING;

EID: 84899494098     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.11.006     Document Type: Article

References (32)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Jackman A.L., Farrugia D.C., Gibson W., Kimbell R., Harrap K.R., Stephens T.C., et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A(7-8):1277-1282.
3. Ferrari V.D., Amoroso V., Valcamonico F., Fusi A., Simoncini E., Vasalli L., et al. Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study. Am J Clin Oncol 2004, 27(5):445-448.
4. Planting A., de Jong M., Jansen P., Kerrebijn J., Smith M., Verweij J. Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. Eur J Cancer 2005, 41(1):93-97.
5. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889.
6. Francois E., Hebbar M., Bennouna J., Mayeur D., Perrier H., Dorval E., et al. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma. Oncology 2005, 68(4-6):299-305.
7. Schwartz G.K., Harstrick A., Gonzalez Baron M. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. Eur J Cancer 1999, 35(Suppl. 1):S9-S13.
8. Nishisho I., Kikkawa N., Ebata T., Osanai H., Ujiie S., Mitachi Y., et al. A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer. Gan To Kagaku Ryoho 2000, 27(1):81-91.
9. Young A., Topham C., Moore J., Turner J., Wardle J., Downes M., et al. A patient preference study comparing raltitrexed ("Tomudex") and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side effects and administration attributes. Eur J Cancer Care (Engl) 1999, 8(3):154-161.
10. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
11. Cunningham D., Zalcberg J.R., Rath U., Oliver I., van Cutsem E., Svensson C., et al. Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 1996, 7(9):961-965.
12. Cocconi G., Cunningham D., Van Cutsem E., Francois E., Gustavsson B., van Hazel G., et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998, 16(9):2943-2952.
13. Maughan T.S., James R.D., Kerr D.J., Ledermann J.A., McArdle C., Seymour M.T., et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359(9317):1555-1563.
14. Ducreux M., Bouche O., Pignon J.P., Mousseau M., Raoul J.L., Cassan P., et al. Randomised trial comparing three different schedules of infusional 5-FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 trial. Oncology 2006, 70(3):222-230.
15. Popov I., Carrato A., Sobrero A., Vincent M., Kerr D., Labianca R., et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008, 44(15):2204-2211.
16. Wu J.B., Wang H.J., Wang S.J., Li L., Feng L. Comparison of raltitrexed plus oxaliplatinl and 5-fluorouracil/leucovorin plus oxaliplatinl in treatment of advanced colorectal carcinoma. China Oncol 2007, 34(09):711-713.
17. Xue H.J., Fan J.Q., Cao R.B., Zhu F., Yao J. Raltitrexed versus fluorouracil/leucovorin combined with oxaliplatin for advanced colorectal cancer: a prospective study. Chin J Postgrad Med 2011, 34(4):7-10.
18. Ning C., Wang Y., Wang Z.G. Raltitrexed plus oxaliplatinl in treatment of senile advanced colorectal carcinoma. Hainan Med J 2011, 22(10):61-63.
19. Fu X.Y., Zhang H.W., Li C.L., Cui Y., Yang H.M., Xiao Y. Raltitrexed combined with oxaliplatinl in the treatment of advanced colorectal cancer. J Clin Med Pract 2012, 16(07):88-90.
20. Gravalos C., Salut A., Garcia-Giron C., Garcia-Carbonero R., Leon A.I., Sevilla I., et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol 2012, 14(8):606-612.
21. Wang J.L., Li J., Qin S.K., Chen Y., Zhang Q.Y., Liu T.S., et al. Randomized multicenter phase III trial of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouraeil and leucovorin for advanced colorectal cancel. Chin Clin Oncol 2012, 17(01):6-11.
22. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G., Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25(2 Suppl. 5):4-12.
23. Van Cutsem E., Cunningham D., Maroun J., Cervantes A., Glimelius B., Raltitrexed: current clinical status and future directions. Ann Oncol 2002, 13(4):513-522.
24. Fizazi K., Ducreux M., Ruffie P., Bonnay M., Daniel C., Soria J.C., Phase I., et al. dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000, 18(11):2293-2300.
25. Scheithauer W., Kornek G.V., Ulrich-Pur H., Penz M., Raderer M., Salek T., et al. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial. Cancer 2001, 91(7):1264-1271.
26. Seitz J.F., Bennouna J., Paillot B., Gamelin E., Francois E., Conroy T., et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002, 13(7):1072-1079.
27. Cortinovis D., Bajetta E., Di Bartolomeo M., Dognini G., Beretta E., Ferrario E., et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. Tumori 2004, 90(2):186-191.
28. Cascinu S., Graziano F., Ferrau F., Catalano V., Massacesi C., Santini D., et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002, 13(5):716-720.
29. Massacesi C., Santini D., Rocchi M.B., La Cesa A., Marcucci F., Vincenzi B., et al. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anticancer Drugs 2003, 14(7):533-541.
30. Kelly C., Bhuva N., Harrison M., Buckley A., Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013, 49(10):2303-2310.
31. Cunningham D., Zalcberg J., Maroun J., James R., Clarke S., Maughan T.S., et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. A review of phase II/III trials. Eur J Cancer 2002, 38(4):478-486.
32. Stewart L.A., Tierney J.F. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002, 25(1):76-97.